A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This study tests the combination of glofitamab (a bispecific antibody that helps the immune system attack cancer cells) plus gemcitabine and oxaliplatin (standard chemotherapy) for people in the United States with diffuse large B-cell lymphoma (DLBCL), a type of aggressive blood cancer, that has come back or stopped responding to treatment. **You may be eligible if...** - You have been diagnosed with DLBCL (confirmed by pathology) - Your lymphoma has relapsed (came back after 6+ months of remission) or is refractory (did not respond or came back within 6 months) - You have received at least one prior treatment - If you have only had one prior treatment, you are not eligible for or cannot tolerate high-dose chemo plus stem cell transplant - You have at least one measurable tumor **You may NOT be eligible if...** - You have a different type of lymphoma - You have not tried any prior treatments - You are able to undergo stem cell transplant (if this was your first line of treatment) - You have significant heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.